Top

BY Scott Merville

As his first official act of Nobel Week, 2018 Nobel Laureate in Physiology or Medicine Jim Allison, Ph.D., on Thursday signed the bottom of a chair at Bistro Nobel in the Nobel Museum in Stockholm’s Old Town. The chair-signing is part of a traditional museum visit by Nobel winners, and launches the week’s events.

Allison, chair of Immunology at MD Anderson, along with co-winner Tasuku Honjo, M.D., Ph.D., of Kyoto University...

 Jim Allison, Ph.D., signed the bottom of a chair at Bistro Nobel in the Nobel Museum in Stockholm

BY Scott Merville

Lung cancer immunotherapy triggers a counterattack by a surface protein found on the tumors of some patients that stifles the immune system...

BY Scott Merville

MD Anderson researchers have uncovered a genetic condition that thwarts the most common immunotherapy used against lung cancer, opening new...

BY Scott Merville

A study led by MD Anderson found the investigational drug quizartinib prolongs overall survival for patients with a deadly form of acute myeloid leukemia (AML) linked to a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD).

“Currently, there are no approved targeted therapies for patients with relapsed FLT3-ITD-associated AML, which represent a significant unmet medical need,” said Jorge Cortes, M.D., deputy...

acute myeloid leukemia cells

BY Scott Merville

When Elizabeth White started a new job as executive director of the Michigan Ovarian Cancer Alliance in 2017, she decided it...

BY Scott Merville

Immunotherapy has taken hold as an effective treatment for a variety of advanced cancers, but so far, colorectal cancer has...

BY Scott Merville

Immune cells that rush to repair damage caused by inflammatory tissue are subverted to cancer-promoting allies by pancreas cells that feature...

BY Scott Merville

Melanoma cells are able to evade cancer immunotherapy by using a specific protein to hide from immune system T cells out to seek and destroy...

BY Scott Merville

Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal...

BY Scott Merville

A cold virus engineered to attack the most common and deadly of brain tumors allowed 20% of patients with recurrent glioblastoma to live for...